Shawn Cross Sells 1,500 Shares of Pacira BioSciences (NASDAQ:PCRX) Stock

Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) CFO Shawn Cross sold 1,500 shares of the business's stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $25.01, for a total value of $37,515.00. Following the completion of the sale, the chief financial officer directly owned 105,341 shares of the company's stock, valued at $2,634,578.41. This represents a 1.40% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Shawn Cross also recently made the following trade(s):

• On Tuesday, April 21st, Shawn Cross sold 2,845 shares of Pacira BioSciences stock. The stock was sold at an average price of $25.01, for a total value of $71,153.45.
• On Monday, April 20th, Shawn Cross sold 7,714 shares of Pacira BioSciences stock. The stock was sold at an average price of $25.14, for a total value of $193,929.96.

Pacira BioSciences Price Performance

Shares of NASDAQ:PCRX opened at $24.88 on Thursday. Pacira BioSciences, Inc. has a fifty-two week low of $18.80 and a fifty-two week high of $27.64. The business has a 50-day moving average of $22.96 and a two-hundred day moving average of $23.06. The stock has a market capitalization of $1.01 billion, a P/E ratio of 165.87 and a beta of 0.19. The company has a debt-to-equity ratio of 0.54, a current ratio of 4.54 and a quick ratio of 3.28.

---

---

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last posted its quarterly earnings data on Thursday, February 26th. The company reported $0.57 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.85 by ($0.28). The firm had revenue of $196.87 million for the quarter, compared to the consensus estimate of $201.93 million. Pacira BioSciences had a return on equity of 10.39% and a net margin of 0.97%.Pacira BioSciences's quarterly revenue was up 5.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.91 earnings per share. On average, equities research analysts predict that Pacira BioSciences, Inc. will post 1.85 EPS for the current fiscal year.

Institutional Trading of Pacira BioSciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Inspire Investing LLC grew its holdings in Pacira BioSciences by 3.2% in the 4th quarter. Inspire Investing LLC now owns 17,958 shares of the company's stock valued at $465,000 after buying an additional 556 shares during the last quarter. Hantz Financial Services Inc. increased its holdings in shares of Pacira BioSciences by 175.4% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,132 shares of the company's stock worth $29,000 after purchasing an additional 721 shares during the period. State of Wyoming increased its holdings in shares of Pacira BioSciences by 7.0% during the 4th quarter. State of Wyoming now owns 11,155 shares of the company's stock worth $289,000 after purchasing an additional 728 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in shares of Pacira BioSciences by 8.0% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 10,604 shares of the company's stock worth $259,000 after purchasing an additional 785 shares during the period. Finally, Franklin Resources Inc. increased its holdings in shares of Pacira BioSciences by 2.6% during the 4th quarter. Franklin Resources Inc. now owns 33,860 shares of the company's stock worth $876,000 after purchasing an additional 846 shares during the period. Institutional investors and hedge funds own 99.73% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on PCRX. Barclays decreased their price objective on shares of Pacira BioSciences from $27.00 to $25.00 and set an "equal weight" rating for the company in a report on Thursday, March 26th. Wall Street Zen downgraded shares of Pacira BioSciences from a "strong-buy" rating to a "buy" rating in a report on Saturday, February 28th. Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Pacira BioSciences in a report on Monday, December 29th. Needham & Company LLC reaffirmed a "buy" rating and issued a $30.00 target price on shares of Pacira BioSciences in a report on Friday, January 9th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $38.00 target price on shares of Pacira BioSciences in a report on Friday, January 9th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $30.25.

Read Our Latest Research Report on Pacira BioSciences

Pacira BioSciences Company Profile

(Get Free Report)

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company's flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.

Further Reading

• Five stocks we like better than Pacira BioSciences

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].